Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
245 hedge funds and large institutions have $5.8B invested in Avidity Biosciences in 2024 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 86 increasing their positions, 62 reducing their positions, and 23 closing their positions.
213% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 23
43% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $7.5M
39% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 62
27% more capital invested
Capital invested by funds: $4.57B → $5.8B (+$1.22B)
25% more funds holding
Funds holding: 196 → 245 (+49)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
9.22% less ownership
Funds ownership: 117.09% → 107.87% (-9.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$142M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$140M |
| 3 |
State Street
Boston,
Massachusetts
|
+$60.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$53.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$50M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$210M |
| 2 |
RI
RTW Investments
New York
|
-$29.2M |
| 3 |
Morgan Stanley
New York
|
-$27.9M |
| 4 |
AG
Artal Group
Luxembourg
|
-$26.8M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$24.9M |
RNAM Hedge Fund Activity: Q3 2024 in Review
245 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2024, worth a combined $5.8B — up 27% from $4.57B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new RNAM positions and 23 closed out — a net gain of 49 holders — while 86 added to existing stakes and 62 trimmed.
The largest buyer was Vanguard Group, adding an estimated $142M. The largest seller was Cowen and Company, exiting entirely with an estimated $210M sold.
- 245 institutional investors held Avidity Biosciences (RNAM) as of Q3 2024, up from 196 in Q2 2024.
- Funds reported $5.8B of Avidity Biosciences stock for Q3 2024, up 27% quarter-over-quarter.
- 72 funds opened new Avidity Biosciences positions in Q3 2024 and 23 closed out, a net change of +49 holders.
- The largest Avidity Biosciences buyer in Q3 2024 was Vanguard Group, an estimated $142M added.
- The largest Avidity Biosciences seller in Q3 2024 was Cowen and Company, an estimated $210M sold.
Based on aggregated 13F filings for Q3 2024.